Stephen E. Jones

发表

Stephen E. Jones, S. Salmon, 1990 .

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

David Miles, Shailendra Verma, Chris Twelves, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Delphi‐panel analysis of appropriateness of high‐dose chemotherapy and blood cell or bone marrow autotransplants in women with breast cancer

G. Hortobagyi, S. Martino, A. Buzdar, 2000, Clinical transplantation.

Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.

H. Putter, D. Rea, R. Paridaens, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I I, R andomized, D ouble-Blind S tudy o f T wo D ose L evels of A rzoxifene i n P atients W ith L ocally A dvanced o r M etastatic Breast C ancer

C. Hudis, D. Booser, A. Buzdar, 2003 .

Antiaromatase agents: evolving role in adjuvant therapy.

Stephen E. Jones, 2002, Clinical breast cancer.

Computed tomographic angiography in stroke imaging: fundamental principles, pathologic findings, and common pitfalls.

Rajiv Gupta, Stephen E. Jones, S. Pomerantz, 2006, Seminars in ultrasound, CT, and MR.

Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer

H. Putter, D. Rea, C. Seynaeve, 2012 .

Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer.

H. Putter, D. Rea, A. D. de Craen, 2012, JAMA.

Long-Term Follow-Up of the Intergroup Exemestane Study.

P. Lønning, L. Fallowfield, R. Paridaens, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P. Lønning, J. Forbes, R. Paridaens, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel-containing adjuvant chemotherapy in patients with early stage breast cancer. Consistency of effect independent of nodal and biomarker status: a meta-analysis of 14 randomized clinical trials

N. Magné, P. Ellis, S. Laporte, 2012, Breast Cancer Research and Treatment.

Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib.

H. Gómez, S. Nag, R. Paridaens, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) comparing docetaxel + cyclophosphamide (TC) v anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative br

H. Gómez, N. Robert, C. Geyer, 2016 .

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma

Anthony Howell, Wolfgang Eiermann, Walter Jonat, 1998, Cancer.

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma

C. Osborne, A. Howell, J. Robertson, 2005, Cancer.

A Phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma

A. Buzdar, C. Vogel, J. Wolter, 1997 .

The effect of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis of the US, German, Netherlands, and Belgium sub-studies

J. Nortier, Stephen E. Jones, A. Hasenburg, 2011, Journal of Cancer Research and Clinical Oncology.

Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen

Stephen E. Jones, J. H. Cheek, G. Peters, 2004, Breast Cancer Research and Treatment.

Implications of the NIH Consensus Development Conference on the Treatment of Early-Stage Breast Cancer

Stephen E. Jones, 1991 .

The effect of tamoxifen or exemestane on bone mineral density during the first 2 years of adjuvant treatment of postmenopausal women with early breast cancer.

F. Holmes, J. Pippen, Stephen E. Jones, 2008, Clinical breast cancer.

Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P288 Effects of exemestane or tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial: a meta-analysis

Stephen E. Jones, A. Hasenburg, P. Hadji, 2011 .

CHEMOTHERAPY OF LOCALISED HISTIOCYTIC LYMPHOMA

Stephen E. Jones, ThomasP. Miller, 1979, The Lancet.

Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer.

J. Pippen, Stephen E. Jones, 2005, Clinical breast cancer.

Comparison of Different Trials of Adjuvant Chemotherapy in Stage II Breast Cancer Using a Natural History Data Base

T. Powles, G. Bonadonna, Stephen E. Jones, 1987, American journal of clinical oncology.

Considerations in treatment choice for metastatic breast cancer

Stephen E. Jones, 2008, Breast cancer.

Radiologic-Pathologic Conference of the Massachusetts General Hospital

T. McLoud, M. Mullins, Stephen E. Jones, 2012 .

Abstract P6-11-09: Heavily pre-treated breast cancer patients show promising responses in the first in human study of the first-In-class fatty acid synthase (FASN) inhibitor, TVB-2640 in combination with paclitaxel

A. Brenner, H. Burris, J. Infante, 2017 .

An Economic Evaluation of Docetaxel and Paclitaxel Regimens in Metastatic Breast Cancer in the UK

D. Cameron, Stephen E. Jones, Á. Benedict, 2012, PharmacoEconomics.

Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study

L. Dirix, M. Kaufmann, Stephen E. Jones, 1999 .

Head-to-head: docetaxel challenges paclitaxel

Stephen E. Jones, 2006 .

Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women: A prospective combined analysis of two multicenter trials

A. Howell, A. Buzdar, I. Vergote, 2004 .

A New Estrogen Receptor Antagonist – An Overview of Available Data

Stephen E. Jones, 2002, Breast Cancer Research and Treatment.

Fulvestrant: an estrogen receptor antagonist that downregulates the estrogen receptor.

Stephen E. Jones, 2003, Seminars in oncology.

Erratum: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials (Cancer (1998) 83 (1142-1152))

A. Howell, A. Buzdar, C. Blomqvist, 1999 .

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

F. Holmes, J. O’Shaughnessy, J. Pippen, 2010 .

Development of a Bioassay for Putative Human

Stephen E. Jones, S. Salmon, Anne, 2005 .

Phase II trial of esorubicin (4′ deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma

T. Miller, H. Garewal, Stephen E. Jones, 2004, Investigational New Drugs.

Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.

F. Holmes, J. O’Shaughnessy, J. Pippen, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitoxantrone in malignant lymphoma

Stephen E. Jones, R. Gams, G. Dukart, 2004, Investigational New Drugs.

Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials.

Stephen E. Jones, 2006, Clinical breast cancer.

α-Difluoromethylornithine as Treatment for Metastatic Breast Cancer Patients

J. O’Shaughnessy, Stephen E. Jones, L. Demers, 1999 .

ICI 182,780 (Faslodex™) versus anastrozole (Arimidex™) for the treatment of advanced breast cancer in postmenopausal women — prospective combined analysis of two multicenter trials

M. Ellis, A. Howell, J. Robertson, 2001 .

Comprehensive Radiotherapy for Advanced Hodgkin's Disease Refractory to Chemotherapy 1

Stephen E. Jones, R. Heusinkveld, A. Feen, 1978 .

Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer

Stephen E. Jones, R. Mennel, B. Brooks, 1988, Investigational New Drugs.

Trends in the Adjuvant Treatment of Breast Cancer

Stephen E. Jones, 1993 .

99mTc sestamibi uptake by acute pulmonary embolism.

James A Scott, C. Wittram, Stephen E. Jones, 2006, AJR. American journal of roentgenology.

Capecitabine (Xeloda) in 162 patients with paclitaxel-pretreated mbc: updated results and analysis of dose modification

A. Buzdar, Stephen E. Jones, J. Blum, 2001 .

PALOMA-2: Primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC).

K. Gelmon, H. Rugo, N. Harbeck, 2016 .

Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors

Stephen E. Jones, S. Salmon, A. Robertone, 2004, Investigational New Drugs.

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

P. Lønning, L. Fallowfield, L. Gibson, 2004, The New England journal of medicine.

A planned comparison of menopausal symptoms during the first year in 1,000 patients receiving either exemestane or tamoxifen in a double-blind adjuvant hormonal study

J. O’Shaughnessy, J. Pippen, Stephen E. Jones, 2004 .

Palbociclib and Letrozole in Advanced Breast Cancer.

K. Gelmon, H. Rugo, N. Harbeck, 2016, The New England journal of medicine.

A clinical evaluation of indium‐111 bleomycin as a tumor‐imaging agent

Stephen E. Jones, S. Salmon, R. O'mara, 1975, Cancer.

Radionuclides in oncology

Stephen E. Jones, S. E. Jones, 1976, La Ricerca in clinica e in laboratorio.

Clinical features and course of the non-Hodgkin's lymphomas

Stephen E. Jones, 1974 .

Rheumatoid meningitis: radiologic and pathologic correlation.

T. McLoud, M. Mullins, Stephen E. Jones, 2006, AJR. American journal of roentgenology.

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.

R. Coombes, L. Fallowfield, E. Hall, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer

Stephen E. Jones, T. Moon, F. Ahmann, 1988, Journal of surgical oncology.

Aneurysm of an Aberrant Right Subclavian Artery Presenting as Dysphagia Lusoria

Stephen E. Jones, Declan Johnson, T. Delap, 2000, The Annals of otology, rhinology, and laryngology.

Importance of systematic review of rotating projection images from Tc99m-sestamibi cardiac perfusion imaging for noncardiac findings

James A Scott, Stephen E. Jones, T. Yasuda, 2008, Nuclear medicine communications.

Incidence of liver involvement and correlation of biopsy results with Ann Arbor clinical criteria and response to chemotherapy in advanced Hodgkin’s disease: A Southwest Oncology Group study

C. Mansfield, F. Morrison, C. Fabian, 1985 .

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

Hein Putter, Christos Markopoulos, Annette Hasenburg, 2011, The Lancet.

Commentary on “Resistance to Endocrine Therapy of Breast Cancer: Recent Advances and Tomorrow's Challenges”

Stephen E. Jones, 2001 .

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.

N. Robert, F. Holmes, J. O’Shaughnessy, 2013, The Lancet. Oncology.

Guidelines for systemic therapy of early stage breast cancer

J. Fay, N. Senzer, Stephen E. Jones, 1997, Breast Cancer Research and Treatment.

Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.

H. Putter, R. Paridaens, C. Seynaeve, 2009 .

Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer.

G. Clark, J. Pippen, Stephen E. Jones, 2002, Clinical breast cancer.

Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women

M. Ellis, A. Howell, J. Robertson, 2003, Cancer.

Hormonal therapy in breast cancer and predominant visceral disease: effectiveness of the new oral aromatase inactivator, Aromasin® (exemestane), in advanced breast cancer patients having progressed on antiestrogens

M. Kaufmann, Stephen E. Jones, A. Polli, 1999 .

Predictive value of bone scans in an adjuvant breast cancer program

J. Woolfenden, Stephen E. Jones, S. Salmon, 1978, Cancer.

The Management of Cancer in the Pregnant Patient

N. Senzer, C. Stringer, Stephen E. Jones, 1991 .

Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging

S E Harms, S. Harms, Stephen E. Jones, 1996, Cancer.

Radiation consolidation following MOP-BAP for stages III & IV Hodgkin's disease, A randomized Southwest Oncology study

R. Fisher, T. Miller, C. Coltman, 1991 .

Improved survival of patients with advanced breast cancer treated with adriamycin-cyclophosphamide plus tamoxifen (TAC)

Stephen E. Jones, T. Moon, F. Ahmann, 1981 .

Development and Use of a Natural History Data Base of Breast Cancer Studies

T. Powles, G. Bonadonna, Stephen E. Jones, 1987, American journal of clinical oncology.

Metastatic breast cancer: the treatment challenge.

Stephen E. Jones, 2008, Clinical breast cancer.

Safety and tolerability of lapatinib in combination with taxanes (T) in patients with breast cancer (BC)

M. Koehler, H. Burris, J. Crown, 2007 .

Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).

H. Gómez, N. Robert, C. Geyer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

H. Koeppen, F. Holmes, J. O’Shaughnessy, 2015, Clinical Cancer Research.

Effect of local therapy on locoregional recurrence in postmenopausal women with breast cancer in the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial.

H. Putter, D. Rea, R. Paridaens, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article.

Stephen E. Jones, M. Clampitt, M. Griswold, 2013, Journal of neurosurgery.

Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer.

E. Montoya, M. Weinstein, E. Winer, 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Phase II evaluation of carboplatin and VP‐16 for patients with metastatic breast cancer and only one prior chemotherapy regimen

Stephen E. Jones, R. Mennel, M. Savin, 1993, Cancer.

The indeterminate CT pulmonary angiogram: imaging characteristics and patient clinical outcome.

C. Wittram, Stephen E. Jones, Conrad Wittram, 2005, Radiology.

104. Randomized phase III study of the new selective aromatase inhibitor arimidex (A) (ZD1033) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer

A. Buzdar, J. Wolters, Stephen E. Jones, 1995 .

Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials

Bingshu E. Chen, R. Gray, P. Lønning, 2023, The Lancet.

Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.

H. Putter, R. Paridaens, C. Seynaeve, 2009 .

The effect of tamoxifen (T) or exemestane (E) on bone mineral density (BMD) after 1 year of adjuvant treatment of postmenopausal women with early breast cancer

J. O’Shaughnessy, J. Pippen, Stephen E. Jones, 2005 .

Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer.

C. Hudis, D. Booser, A. Buzdar, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease

C. Coltman, W. Knight, C. Fabian, 1983, Investigational new drugs.

Capecitabine plus docetaxel combination therapy

J. Hornberger, D. Miles, J. O’Shaughnessy, 2005, Cancer.

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

A. Buzdar, H. Burger, P. LoRusso, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Initial chemotherapy for clinically localized lymphomas of unfavorable histology.

T. Miller, Stephen E. Jones, S. Jones, 1983, Blood.

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.

B. Overmoyer, P. Ravdin, W. Urba, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide.

D. Alberts, M. Aapro, Stephen E. Jones, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Computed tomographic scanning in patients with lymphoma

D. A. Tobias, Stephen E. Jones, S. Jones, 1978, Cancer.

The role of radionuclides in clinical oncology.

Stephen E. Jones, S. Salmon, S. Jones, 1976, Seminars in nuclear medicine.

Is there a role for radiotherapy in localized diffuse lymphomas?

T. Miller, Stephen E. Jones, S. Jones, 2004, Cancer Chemotherapy and Pharmacology.

Intravenous vinorelbine as first-line and second-line therapy in advanced breast cancer.

B. Weber, L. Hutchins, C. Vogel, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

P. Lønning, J. Forbes, R. Coombes, 2007, The Lancet.

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

L. Dirix, M. Kaufmann, Stephen E. Jones, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy.

J. Connors, T. Miller, Stephen E. Jones, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer.

F. Holmes, J. O’Shaughnessy, Stephen E. Jones, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

L. R. Hill, F. Holmes, J. O’Shaughnessy, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

S. Swain, C. Vogel, S. Wadler, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical activity of GW572016 in EGF10003 in patients with solid tumors.

David A. Smith, A. Stead, G. Wilding, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

P. Lønning, L. Fallowfield, L. Gibson, 2004 .

A phase II study of bisantrene in malignant lymphomas

T. Miller, Stephen E. Jones, J. Cowan, 2004, Cancer Chemotherapy and Pharmacology.

Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: A Southwest Oncology Group phase II trial

Stephen E. Jones, S. Dahlberg, B. Schnitzer, 1989, Investigational New Drugs.

Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

D. Alberts, T. Miller, Stephen E. Jones, 2004, Investigational New Drugs.

Psychosocial Characteristics of Cancer Patients Who Choose Laetrile Therapy

Stephen E. Jones, L. Beutler, F. Meyskens, 1985 .

Phase I trial of KOS-1584 (a novel epothilone) using two weekly dosing schedules

A. Stopeck, H. Burris, S. Moulder, 2007 .

Chemohormonal therapy for advanced breast cancer with tamoxifen, adriamycin, and cyclophosphamide (TAC)

T. Miller, Stephen E. Jones, T. Moon, 1985, Cancer.

27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination

A. Brenner, H. Burris, J. Infante, 2015 .